Cargando…

Vitamin-K-antagonist phenprocoumon versus direct oral anticoagulants in patients with atrial fibrillation: a real-world analysis of German claims data

OBJECTIVES: Direct oral anticoagulants (DOACs) were introduced based on randomised controlled trials (RCTs) comparing them to vitamin-K-antagonist (VKA) warfarin. In Germany, almost exclusively phenprocoumon is used as VKA. RCTs with phenprocoumon being absent we analysed the benefits and harms of D...

Descripción completa

Detalles Bibliográficos
Autores principales:	Warkentin, Lisette, Klohn, Florian, Deiters, Barthold, Kühlein, Thomas, Hueber, Susann
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	BMJ Publishing Group 2023
Materias:	Pharmacology and Therapeutics
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9809214/ https://www.ncbi.nlm.nih.gov/pubmed/36593002 http://dx.doi.org/10.1136/bmjopen-2022-063490

Ejemplares similares

Vitamin-K-antagonist phenprocoumon versus low-dose direct oral anticoagulants (DOACs) in patients with atrial fibrillation: a real-world analysis of German claims data
por: Warkentin, Lisette, et al.
Publicado: (2022)

Comparison of phenprocoumon with direct oral anticoagulants in catheter ablation of atrial fibrillation
por: Gjermeni, Diona, et al.
Publicado: (2023)

Short- and medium-term cost effects of non-indicated thyroid diagnostics: empirical evidence from German claims data
por: Hafner, Lucas, et al.
Publicado: (2021)

Resolution of left atrial appendage thrombi: No difference between phenprocoumon and non‐vitamin K‐dependent oral antagonists
por: Biller, Katharina, et al.
Publicado: (2022)

Consequences of early thyroid ultrasound on subsequent tests, morbidity and costs: an explorative analysis of routine health data from German ambulatory care
por: Hueber, Susann, et al.
Publicado: (2023)

Phenprocoumon based anticoagulation is an underestimated factor in the pathogenesis of calciphylaxis
por: Russ, Philipp, et al.
Publicado: (2019)

Active monitoring of adverse reactions following COVID-19 and other vaccinations: a feasibility study as part of the CoVaKo project
por: Zeschick, Nikoletta, et al.
Publicado: (2022)

Clinical outcomes in patients receiving edoxaban or phenprocoumon for prevention of stroke in atrial fibrillation: a German real-world cohort study
por: Hohmann, Christopher, et al.
Publicado: (2022)

Vitamin K Antagonists, Non–Vitamin K Antagonist Oral Anticoagulants, and Vascular Calcification in Patients with Atrial Fibrillation
por: Peeters, Frederique E. C. M., et al.
Publicado: (2018)

Non-vitamin K antagonist oral anticoagulants in cancer patients with atrial fibrillation
por: Undas, Anetta, et al.
Publicado: (2020)

Reactogenicity after heterologous and homologous COVID-19 prime-boost vaccination regimens: descriptive interim results of a comparative observational cohort study
por: Warkentin, Lisette, et al.
Publicado: (2022)

Reactogenicity and safety of COVID-19 primary immunisation and booster vaccination regimens: a comparative observational cohort study
por: Warkentin, Lisette, et al.
Publicado: (2023)

Patient-reported reactogenicity and safety of COVID-19 vaccinations vs. comparator vaccinations: a comparative observational cohort study
por: Werner, Felix, et al.
Publicado: (2023)

Non-vitamin K antagonist oral anticoagulants in older and frail patients with atrial fibrillation
por: Giugliano, Robert P
Publicado: (2022)

Use of non-vitamin K antagonists oral anticoagulants in atrial fibrillation patients on dialysis
por: Li, Wenhao, et al.
Publicado: (2022)

Low-dose non-vitamin K antagonist oral anticoagulants in patients with atrial fibrillation
por: Lee, Ki Hong, et al.
Publicado: (2023)

Pharmacokinetics of Phenprocoumon in Emergency Situations–Results of the Prospective Observational RADOA-Registry (Reversal Agent Use in Patients Treated with Direct Oral Anticoagulants or Vitamin K Antagonists Registry)
por: Lindhoff-Last, Edelgard, et al.
Publicado: (2022)

Relation of the ‘Atrial Fibrillation Better Care (ABC) Pathway’ to the Quality of Anticoagulation in Atrial Fibrillation Patients Taking Vitamin K Antagonists
por: Roldán, Vanessa, et al.
Publicado: (2022)

Prediction of phenprocoumon maintenance dose and phenprocoumon plasma concentration by genetic and non-genetic parameters
por: Geisen, Christof, et al.
Publicado: (2010)

Comparative effectiveness and safety of oral anticoagulants for atrial fibrillation in real-world practice: a population-based cohort study protocol
por: Holbrook, Anne, et al.
Publicado: (2016)

Outcomes of left atrial appendage occlusion vs. non-vitamin K antagonist oral anticoagulants in atrial fibrillation
por: Ding, Wern Yew, et al.
Publicado: (2022)

Non-Vitamin K Antagonist Oral Anticoagulants: New Choices for Patient Management in Atrial Fibrillation
por: Saliba, Walid
Publicado: (2015)

Non-Vitamin K Antagonist Oral Anticoagulants in Patients with Atrial Fibrillation and Valvular Heart Disease
por: Moon, Inki, et al.
Publicado: (2019)

Atrial Fibrillation and Stroke. A Review on the Use of Vitamin K Antagonists and Novel Oral Anticoagulants
por: Caturano, Alfredo, et al.
Publicado: (2019)

Optimizing adherence and persistence to non-vitamin K antagonist oral anticoagulant therapy in atrial fibrillation
por: Farinha, José Maria, et al.
Publicado: (2022)

Trends in the Prescription of Non-Vitamin K Antagonist Oral Anticoagulants for Atrial Fibrillation: Results of the Polish Atrial Fibrillation (POL-AF) Registry
por: Gorczyca, Iwona, et al.
Publicado: (2020)

Drug interaction: Omeprazole and Phenprocoumon
por: Enderle, Christa, et al.
Publicado: (2001)

Anticoagulant Treatment Adherence and Persistence in German Patients with Atrial Fibrillation
por: Patti, Giuseppe, et al.
Publicado: (2023)

Shifting from vitamin K antagonists to non-vitamin K antagonist oral anticoagulants in patients with atrial fibrillation: predictors, patterns and temporal trends
por: Shiyovich, Arthur, et al.
Publicado: (2021)

Efficacy and safety of non-vitamin K antagonist oral anticoagulants compared with warfarin in patients with atrial fibrillation
por: Friberg, Leif, et al.
Publicado: (2017)

Effect of Non-vitamin K Antagonist Oral Anticoagulants in Atrial Fibrillation Patients with Newly Diagnosed Cancer
por: Kim, Kyu, et al.
Publicado: (2018)

Non–Vitamin K Antagonist Oral Anticoagulants Versus Warfarin in Atrial Fibrillation Patients With Intracerebral Hemorrhage
por: Nielsen, Peter Brønnum, et al.
Publicado: (2019)

Non-vitamin K antagonist oral anticoagulants therapy for atrial fibrillation patients undergoing electrophysiologic procedures
por: Steffel, Jan
Publicado: (2020)

Risk of Osteoporosis in Patients With Atrial Fibrillation Using Non–Vitamin K Antagonist Oral Anticoagulants or Warfarin
Publicado: (2020)

Social Inequalities of Oral Anticoagulation after the Introduction of Non-Vitamin K Antagonists in Patients with Atrial Fibrillation
por: Yu, Hee Tae, et al.
Publicado: (2019)

Risk of Osteoporosis in Patients With Atrial Fibrillation Using Non–Vitamin K Antagonist Oral Anticoagulants or Warfarin
por: Huang, Huei‐Kai, et al.
Publicado: (2020)

Use of Non-Vitamin K Antagonist Oral Anticoagulants Among Patients with Nonvalvular Atrial Fibrillation and Multimorbidity
por: Deitelzweig, Steven, et al.
Publicado: (2021)

Anticoagulation Control in Different Ethnic Groups Receiving Vitamin K Antagonist for Stroke Prevention in Atrial Fibrillation
por: Zawawi, Nur Azyyati, et al.
Publicado: (2021)

Anticoagulation Control in Older Atrial Fibrillation Patients Receiving Vitamin K Antagonist Therapy for Stroke Prevention
por: Zulkifly, Hanis, et al.
Publicado: (2022)

Real-world effectiveness and safety of oral anticoagulation strategies in atrial fibrillation: a cohort study based on a German claims dataset
por: Mueller, Sabrina, et al.
Publicado: (2018)

Cannot write session to /tmp/vufind_sessions/sess_da6rai3l03umrdpkik2qo5a78v